Anuh Pharma Limited Stock Price Today (NSE: ANUHPHR)
Fundamental Score
Anuh Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anuh Pharma Limited share price today is ₹89.22, down 1.23% on NSE/BSE as of 16 September 2026. Anuh Pharma Limited (ANUHPHR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹894.20 (Cr). The 52-week high for ANUHPHR share price is ₹99.50 and the 52-week low is ₹67.00. At a P/E ratio of 20.23x, ANUHPHR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.10% and a debt-to-equity ratio of 0.00.
Anuh Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Anuh Pharma Limited share price chart: 21.99% return over the past month. 52-week high ₹99.50, 52-week low ₹67.00.
Anuh Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹89.50 | ₹91.99 | ₹87.01 | ₹89.22 | 1.41L (Cr) | |
| ₹95.00 | ₹97.50 | ₹89.91 | ₹90.33 | 2.09L (Cr) | |
| ₹91.20 | ₹95.88 | ₹90.79 | ₹94.86 | 2.22L (Cr) | |
| ₹97.90 | ₹98.88 | ₹90.20 | ₹91.21 | 4.00L (Cr) | |
| ₹96.00 | ₹99.50 | ₹96.00 | ₹96.74 | 6.27L (Cr) | |
| ₹92.00 | ₹99.50 | ₹91.79 | ₹95.53 | 17.50L (Cr) | |
| ₹82.70 | ₹91.80 | ₹82.00 | ₹90.62 | 10.68L (Cr) | |
| ₹80.75 | ₹82.35 | ₹79.70 | ₹81.10 | 80.37K (Cr) | |
| ₹79.30 | ₹81.70 | ₹78.10 | ₹79.68 | 93.22K (Cr) | |
| ₹81.43 | ₹81.93 | ₹78.40 | ₹78.94 | 1.38L (Cr) |
Anuh Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹83.68 | ₹99.50 | ₹78.10 | ₹89.22 | +6.62% | |
| ₹81.47 | ₹85.99 | ₹75.40 | ₹82.04 | +0.70% | |
| ₹81.99 | ₹82.80 | ₹75.50 | ₹79.48 | -3.06% | |
| ₹76.48 | ₹83.90 | ₹75.00 | ₹81.23 | +6.21% | |
| ₹81.20 | ₹86.81 | ₹74.00 | ₹76.10 | -6.28% | |
| ₹78.00 | ₹85.00 | ₹70.15 | ₹81.20 | +4.10% | |
| ₹75.10 | ₹80.00 | ₹67.00 | ₹67.00 | -10.79% | |
| ₹74.19 | ₹85.00 | ₹70.42 | ₹77.16 | +4.00% | |
| ₹82.25 | ₹82.25 | ₹69.27 | ₹72.64 | -11.68% | |
| ₹79.00 | ₹83.67 | ₹76.70 | ₹80.52 | +1.92% | |
| ₹90.80 | ₹90.80 | ₹76.25 | ₹77.02 | -15.18% | |
| ₹84.81 | ₹93.00 | ₹78.42 | ₹89.74 | +5.81% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Anuh Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anuh Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANUHPHR across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.03%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.23 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (37.63%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (12.30% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (115.80x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.11)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹93.61 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (71.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 0.05%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Anuh Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Anuh Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Anuh Pharma LimitedAnuh Pharma Lim...Selected✓ ANUHPHR • 506260 | 51.2/100 | ₹89.22₹89 | ₹894.20₹894.20 | 20.23Average 20.2 Average | 12.10%Average 12.10% Average | 16.03%Good 16.03% Good | 0.00Excellent 0.0 Excellent | 12.78%Good 12.78% Good | 12.30%Good 12.30% Good | 1.87% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1840.00₹1840 | ₹441471.20₹441471.20 | 36.51Average 36.5 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9322.00₹9322 | ₹247033.00₹247033.00 | 84.58Average 84.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4965.50₹4966 | ₹168062.31₹168062.31 | 79.32Average 79.3 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1119.10₹1119 | ₹111686.18₹111686.18 | 24.94Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1366.00₹1366 | ₹110352.31₹110352.31 | 32.73Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1969.00₹1969 | ₹106375.23₹106375.23 | 97.19Average 97.2 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1165.50₹1166 | ₹97319.25₹97319.25 | 30.12Average 30.1 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1679.80₹1680 | ₹96655.69₹96655.69 | 26.25Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2095.00₹2095 | ₹95793.88₹95793.88 | 17.31Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2280.00₹2280 | ₹94164.00₹94164.00 | 46.07Average 46.1 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price441471.20 Cr
- Divi's Laboratories Limited share price247033.00 Cr
- Torrent Pharmaceuticals Limited share price168062.31 Cr
- Zydus Lifesciences Limited share price111686.18 Cr
- Cipla Limited share price110352.31 Cr
Anuh Pharma Limited PE Ratio History
Historical price-to-earnings ratio for ANUHPHR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.72 | ₹80.52 | 17x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Anuh Pharma Limited Dividend History
Annual cash dividends paid by ANUHPHR — dividend yield 1.87%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹12.52 Cr |
| FY 2024 | ₹10.03 Cr |
| FY 2023 | ₹8.75 Cr |
| FY 2022 | ₹7.56 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Anuh Pharma Limited Quarterly Performance
Latest quarterly metrics for ANUHPHR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
3.93%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
37.63%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.30%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.78%
Compounded annual net profit growth over 5 years
Anuh Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ANUHPHR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Anuh Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Anuh Pharma Limited (ANUHPHR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Anuh Pharma Limited
About ANUHPHR (Anuh Pharma Limited)
Anuh Pharma Ltd is a dynamic pharmaceutical manufacturer deeply rooted in the Indian landscape. With a strong focus on bulk drug and chemical production, the company serves as a cr...itical link in the pharmaceutical supply chain. Anuh Pharma boasts a diverse portfolio of active pharmaceutical ingredients (APIs), meticulously crafted to meet the rigorous demands of the global healthcare industry. Their offerings encompass a spectrum of therapeutic categories, reflecting their commitment to addressing a wide range of medical needs. From essential treatments for infectious diseases to innovative solutions for chronic conditions, Anuh Pharma strives to provide high-quality ingredients that contribute to the development of life-enhancing medications. Their strength lies in their understanding of complex chemical processes and their adherence to strict regulatory standards. Beyond its core API offerings, Anuh Pharma demonstrates a commitment to continuous innovation. The company is actively involved in the development of specialized products, including niche chemicals and intermediates, further solidifying its position as a versatile partner within the pharmaceutical sector. This proactive approach to product development allows Anuh Pharma to adapt to the evolving needs of the market and cater to the specific requirements of its clientele. Their expertise extends to several therapeutic areas, reflecting a comprehensive approach to healthcare solutions. This adaptability and dedication to innovation allows Anuh Pharma to make significant strides and add value to its partners. Anuh Pharma's business model revolves around providing reliable and cost-effective solutions to pharmaceutical companies worldwide. Their commitment to quality, consistency, and timely delivery has earned them a reputation as a trusted supplier. By maintaining stringent quality control measures throughout the manufacturing process, Anuh Pharma ensures that its products meet the highest industry standards. This dedication to excellence has fostered long-term relationships with key players in the pharmaceutical industry. Anuh Pharma continues to invest in research and development, as well as, technology, in order to build on their business model and ensure customer satisfaction.
Company Details
Key Leadership
ANUHPHR Share Price: Frequently Asked Questions
What is the current share price of Anuh Pharma Limited?
Anuh Pharma Limited (ANUHPHR) trades at ₹89.22 on NSE and BSE. Market cap ₹894.20 (Cr). Educational data only.
What is the P/E ratio of Anuh Pharma Limited?
Anuh Pharma Limited has a P/E of 20.23x vs industry average 34.89x.
What is the Bull Run score for Anuh Pharma Limited?
Anuh Pharma Limited has a Bull Run score of 51.2/100 based on 25+ financial parameters.
Does Anuh Pharma Limited pay dividends?
Anuh Pharma Limited has a dividend yield of 1.87%. Past dividends don't guarantee future payments.
What is the ROE of Anuh Pharma Limited?
Anuh Pharma Limited has ROE of 12.10%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Anuh Pharma Limited?
Anuh Pharma Limited has debt-to-equity of 0.00.
Is Anuh Pharma Limited a good investment?
Bull Run gives Anuh Pharma Limited a score of 51.2/100. This is not investment advice — consult a SEBI-registered advisor.